First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Enriqueta Felip, Victor Moreno, Daniel Morgensztern, Giuseppe Curigliano, Piotr Rutkowski, José Manuel Trigo, Aitana Calvo, Dariusz Kowalski, Diego Cortinovis, Ruth Plummer, Michele Maio, Paolo A. Ascierto, Vladimir I. Vladimirov, Andres Cervantes, Enrique Zudaire, Anasuya Hazra, Huybrecht T’jollyn, Nibedita Bandyopadhyay, James G. Greger, Edward AttiyehHong Xie, Emiliano Calvo
Dive into the research topics of 'First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers'. Together they form a unique fingerprint.